Future therapy for inflammatory bowel disease: should we rethink what we mean by "top down"?
Farthing
Michael J G
MJ
St. George's, University of London, Cranmer Terrace, London SW17 ORE, UK. m.farthing@sgul.ac.uk
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D005260:Female; D005544:Forecasting; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*; D008297:Male; D011788:Quality of Life; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha